Plasminogen Activator Inhibitor-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight

Jeffrey R. Holzberg, Emory University
Ran Jin, Emory University
Ngoc-Anh Le, Atlanta Veterans Affairs Medical Center
Thomas Ziegler, Emory University
Elizabeth M. Brunt, Washington University
Craig J. McClain, University of Louisville
Juna V. Konomi, Emory University
Gavin E. Arteel, University of Louisville
Miriam Vos, Emory University

Journal Title: Journal of Pediatric Gastroenterology and Nutrition
Volume: Volume 62, Number 6
Publisher: Lippincott, Williams & Wilkins | 2016-06-01, Pages 819-823
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1097/MPG.0000000000001096
Permanent URL: https://pid.emory.edu/ark:/25593/s2xv5

Final published version: http://dx.doi.org/10.1097/MPG.0000000000001096

Copyright information:
© 2016 by ESPGHAN and NASPGHAN.
This is an Open Access work distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Accessed January 25, 2020 8:47 PM EST
PAI-1 Predicts Quantity of Hepatic Steatosis Independent of Insulin Resistance and Body Weight

Jeffrey R. Holzberg, MD1, Ran Jin, PhD2, Ngoc-Anh Le, PhD3, Thomas R. Ziegler, MD1, Elizabeth M. Brunt, MD4, Craig J. McClain, MD5,6, Juna V. Konomi, PhD2, Gavin E. Arteel, PhD5, and Miriam B. Vos, MD, MSPH2,7,8

Jeffrey R. Holzberg: jholzberg@gmail.com; Ran Jin: rjin@emory.edu; Ngoc-Anh Le: anh.le@va.gov; Thomas R. Ziegler: tzieg01@emory.edu; Elizabeth M. Brunt: EBrunt@path.wustl.edu; Craig J. McClain: craig.mcclain@louisville.edu; Gavin E. Arteel: gavin.arteel@louisville.edu; Miriam B. Vos: mvos@emory.edu

1School of Medicine, Emory University, Atlanta, GA
2Department of Pediatrics, School of Medicine, Emory University, Atlanta, GA
3Biomarker Core Laboratory, Atlanta Veterans Affairs Medical Center, Decatur, GA
4Department of Pathology and Immunology, School of Medicine, Washington University, Saint Louis, MO
5Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY
6Department of Medicine, University of Louisville, Louisville, KY
7Nutrition and Health Sciences Program/GDBBS, Emory University, Atlanta, GA
8Children’s Healthcare of Atlanta, Atlanta, GA

Abstract

Objective—To examine the association between PAI-1, an acute phase protein strongly associated with cardiovascular disease risk, and adiposity, insulin resistance, and inflammation among overweight and obese children with a wide range of hepatic steatosis.

Methods—Plasma PAI-1 levels were measured in a prospectively recruited cohort of 39 overweight or obese children who underwent comprehensive anthropometric assessment and metabolic measurements. Hepatic steatosis was quantified using magnetic resonance spectroscopy and participants were divided into 3 groups based on whether they had normal hepatic steatosis (<5%), low hepatic steatosis (5–10%) and high hepatic steatosis (>10%).
Results—Plasma PAI-1 levels significantly increased across the severity of hepatic steatosis in overweight and obese children, and this association was independent of BMI z-score, visceral fat, insulin resistance, and inflammatory markers (p < 0.05).

Conclusion—Hepatic steatosis in children is positively associated with circulating levels of PAI-1 independent of BMI, insulin resistance, and inflammatory markers. Further studies are needed to clarify the potential role of PAI-1 as a therapeutic target in pediatric NAFLD.

Keywords
plasminogen activator inhibitor-1; non-alcoholic fatty liver disease; cardiovascular disease risk; children; insulin resistance

INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide in adults and children (1, 2) and ranges from simple steatosis to steatohepatitis (NASH), fibrosis and liver cirrhosis (3). NAFLD is closely intertwined with features of metabolic syndrome, most notably obesity, insulin resistance and dyslipidemia (4, 5), as well as an increased risk of cardiovascular disease (CVD) (2, 6–8).

The exact metabolic pathways that underlie the development of hepatic steatosis remain poorly understood, as does the link between NAFLD and CVD (9, 10). Among proposed mechanisms, the fibrinolytic system raises particular interest because of demonstrated association with NAFLD (11), insulin resistance (8), and atherosclerosis (12). Plasminogen activator inhibitor-1 (PAI-1) is an acute-phase protein in the fibrinolytic pathway produced by both hepatocytes and adipocytes, and appears to be elevated in obesity, dyslipidemia, and insulin resistance (8, 13). Recent studies have shown PAI-1 to be associated with hepatic steatosis (14–17) and NAFLD severity (18). Animal models suggest a causal role for PAI-1 and NAFLD onset through suppression of lipid export from the liver (19). However, other studies suggest that the association between elevated PAI-1 and hepatic steatosis may be mediated by the presence of obesity and insulin resistance (20, 21). Therefore, understanding the role of PAI-1 in the development of NAFLD, particularly at this early life stage, is crucial as it may serve as a potential therapeutic target for children with NAFLD.

In the current study, we measured plasma PAI-1 levels in a group of overweight or obese children and assessed its relationship with hepatic steatosis precisely measured by MRS technique, while considering factors such as visceral adiposity, insulin resistance and inflammation. We hypothesized that PAI-1 would be more closely associated with steatosis than with BMI, insulin resistance, or systemic inflammation.

METHODS

Study Design

This study was conducted at the Atlanta Clinical and Translational Science Institute Clinical Research Units at Children’s Healthcare of Atlanta (CHOA) and Emory University Hospital. Subjects were prospectively recruited from pediatric clinics at Emory University Children’s Hospital.
Center and from nearby community centers through flyers and presentations at community events. Written informed consent was obtained from a parent or guardian and written assent was obtained from all children 11 years and older before participation. The protocols were approved by the Institutional Review Boards for Human Subject Research for Emory University and CHOA.

**Patient Characteristics**

A total of 39 children participated in our study. Inclusion criteria were ages 11–18 years; self-identified as Hispanic; body mass index (BMI) ≥85th percentile for age and gender; and an average self-reported consumption of at least 3 sugar-containing drinks per day. High consumption of sugar-containing beverages was an inclusion criterion in order to increase the likelihood of finding adolescents with significant hepatic steatosis (22). Exclusion criteria included known liver diseases; diabetes or fasting glucose ≥126 mg/dL; renal insufficiency (creatinine > 2 mg/dL); any chronic diseases requiring daily medication; acute illness within 2 weeks prior to enrollment (defined by fever > 100.4°F); and supplement or anti-oxidant therapy within 4 weeks prior to enrollment. Body weight, height, and blood pressure were recorded. The age- and gender-specific BMI z-score were calculated (23). To calculate insulin resistance, the homeostasis model assessment of insulin resistance (HOMA-IR) (24), and adipose tissue insulin resistance index (Adipo-IR) (25) were used.

**Laboratory Analysis**

Blood samples were collected in the morning following a 12-hour overnight fast in EDTA-coated tubes and plasma was separated immediately upon collection. Plasma samples were protected from light and transported in ice packs to the laboratory for further processing (within 4 hours). Plasma concentrations of aspartate aminotransferase (AST), alanine aminotransferase (ALT) and γ-glutamyl transpeptidase (GGT) were measured by routine enzymatic methods at CHOA Clinical Laboratory. Plasma concentrations of PAI-1 and tumor necrosis factor -alpha (TNF-α) were measured by multi-analyte chemiluminescent detection assay using Luminex® xMap technology (Millipore Corporation, St. Louis, MO).

All lipid measurements were performed by the Biomarker Core Laboratory at the Atlanta Veterans Affairs Medical Center using AU480 chemistry analyzer (Beckman Coulter, LaBrea, CA). Total cholesterol and triglycerides (TG) were measured by enzymatic methods using reagents from Beckman (Beckman Diagnostics, Fullerton, CA). Low-density lipoproteins (LDL) and high-density lipoproteins (HDL) were measured by homogeneous enzymatic assays (Sekisui Diagnostics, Exton, PA). Free fatty acids (FFA) and glucose concentrations were determined by colorimetric method (Sekisui Diagnostics, Exton, PA). Plasma fasting insulin level (μU/ml) was assessed using immunoturbidimetric methods (Sekisui Diagnostics, Exton, PA).

**Measurements of hepatic steatosis and visceral adiposity**

Hepatic steatosis was assessed by magnetic resonance spectroscopy (MRS) using our previously described methods (26). Briefly, we used a rapid 15-sec acquisition technique obtained during a single breath hold. Water and lipid magnitude spectra were analyzed by determining the AUC corresponding to a user-defined frequency range surrounding the
corresponding water/lipid peaks (water peak: 4.6ppm; lipid peak: 1.3, 2.0ppm). The integrated magnitude signals at each TE were fit to exponential T2 decay curves, whereby the equilibrium signal ($M_0$) and the relaxation rate ($R_2=1/T_2$) were determined by least-squares approximation. Using $M_0$ for water and lipid, the T2-corrected hepatic lipid fraction was calculated from: % Hepatic Lipid = $M_0$[lipid]/($M_0$[lipid] + $M_0$[water]). The calculated percentage of steatosis was then grouped depending on whether the MRS indicated normal hepatic fat content (NHF, < 5%), low hepatic fat content (LHF, ≥5–10%), or high hepatic fat content (HHF, > 10%).

Visceral adiposity was calculated using ImageJ software (NIH, Bethesda, MD). From a 3D gradient-echo acquisition with a 3-point Dixon reconstruction (27), a single, “fat-only” image was isolated at the L4 vertebral body. A signal threshold was set manually for each subject such that the subcutaneous fat was completely identified (>90% of maximum signal). This threshold was automatically extended to the visceral region, producing a binary mask of fat and non-fat regions. Manual segmentation was performed to separate subcutaneous and visceral regions by using the intra-abdominal muscle and perineum as boundary landmarks. The vertebra was not included in the segmented region. Visceral adiposity was calculated from the threshold volume of the segmented intra-abdominal region.

**Statistical Analysis**

Statistical analyses were performed using SAS 9.3 (SAS Institute, Cary, NC). To compare variables across three categories of hepatic steatosis (NHF, LHF, and HHF), ANOVA tests or Kruskal-Wallis tests (for variables without normal distribution) were used. Data are expressed as mean (± standard error), with statistical significance considered as a p-value ≤ 0.05. Linear regression models were performed to determine the independent association between plasma PAI-1 levels and hepatic steatosis, after adjusting for covariates including BMI z-score, visceral adiposity, insulin resistance, and inflammatory markers.

**RESULTS**

**Baseline Characteristics of Participants**

Demographic characteristics and baseline variables are presented in Table 1. Study participants were categorized into three groups based upon quantification of hepatic steatosis. Of the 39 Hispanic, overweight or obese children, 12 (30.8%) had normal hepatic fat (NHF, < 5%), 14 (35.9%) had low hepatic fat (LHF, ≥5–10%), and 13 (33.3%) had high hepatic fat (HHF, > 10%). Significant differences were observed in BMI z-score, visceral adiposity, and percent of hepatic steatosis between the groups. Additionally, indices of insulin resistance, plasma triglyceride and free fatty acid content were significantly different across the three categories of hepatic steatosis (Table 1). No statistically significant differences were observed for glucose, cholesterol, LDL, HDL measurements, or for inflammatory markers (Table 1).
**Association between plasma PAI-1 and Hepatic Steatosis**

Figure 1 illustrates the difference in PAI-1 plasma concentration across the groups with variable hepatic steatosis. PAI-1 levels were significantly lower in individuals with normal hepatic fat (8.78 ± 1.17 ng/mL) when compared to those in individuals with low hepatic fat (11.6 ± 0.99 ng/mL, p = 0.04) and high hepatic fat (20.8 ± 2.26 ng/mL, p < 0.001). Additionally, significant differences in PAI-1 plasma levels were observed between low and high hepatic fat groups (p = 0.002).

To further assess the relationship between PAI-1 and hepatic steatosis, linear regression models were performed. Plasma PAI-1 levels were independently associated with hepatic steatosis after adjusting for BMI z-score, visceral adiposity, insulin resistance indices, ALT, and TNF-α (Table 2). When further adjustment was made for plasma TG, the association between plasma PAI-1 levels and hepatic steatosis was attenuated and lost statistical significance.

**DISCUSSION**

By using a well characterized cohort of overweight or obese children with a wide range of hepatic steatosis, precisely quantified by MRS, we demonstrated that plasma PAI-1 levels were related to the amount of hepatic steatosis independent of BMI, visceral fat, insulin resistance indices, and inflammatory markers. This finding is in contrast to previous conclusions that PAI-1 is more closely related to body weight and insulin resistance. Our study supports an independent role for PAI-1 in the mechanisms of NAFLD and its consideration as a possible therapeutic target for both NAFLD and the NAFLD-associated CVD risk.

Until the development of MRI-based hepatic steatosis quantification methods, it was difficult to characterize hepatic steatosis precisely, which could in part explain previously reported conflicting results in regards to PAI-1 levels and hepatic steatosis. A study by de Larrañaga et al. in which adult patients at risk for metabolic syndrome underwent liver ultrasound scans to measure hepatic steatosis, concluded that plasma PAI-1 levels were better determined by whole-body fat content than liver steatosis content, after controlling for features of metabolic syndrome (28). Targher et al. showed that in healthy adult men the association between ultrasound-diagnosed NAFLD and PAI-1 was no longer apparent after adjusting for CT-measured visceral adiposity (29). Alessi et al. countered by showing that PAI-1 levels were more closely related to liver steatosis than visceral adiposity in obese versus healthy adults who underwent liver biopsy, however it is unclear how many cases of fatty liver were alcohol-induced (17). Previous studies in children found an association between PAI-1 and hepatic steatosis similar to ours, however they did not control for BMI in their analyses (30, 31).

Previous studies using a murine cell culture model of hepatocytes suggest that the relationship of PAI-1 and hepatic steatosis is via suppression of microsomal triglyceride transfer protein (MTTP) activity by PAI-1 and resultant accumulation of triglycerides in cells (32). Similarly, PAI-1 knockout mice were protected from fructose-induced hepatic steatosis and liver damage through effects on hepatic lipid export (33). Pharmaceutical
treatment with losartan, a medication that reduces PAI-1 levels, has been shown to strongly reduce hepatic PAI-1 expression and reverse hepatic steatosis and lipid accumulation in rats (34). Thus, while PAI-1 is best known for its other biologic roles in the fibrinolytic pathway, it appears to be active in modification of lipid regulation in the liver as well. This makes PAI-1 a promising therapeutic target in adults and children with NAFLD.

The major strengths of this study include the use of MRS to precisely quantify hepatic and visceral steatosis in children with NAFLD and overweight or obese controls. MRS methodology provides a precise and non-invasive measure of hepatic fat and has been shown to have close correlation with the gold standard procedure of liver biopsy ($r = 0.9$) (35). All data collection and evaluation were performed in a dedicated pediatric research center and the children were extensively characterized allowing comparisons between the liver, whole body adiposity, and insulin sensitivity. Our study is subjected to limitations given its cross-sectional nature. By adjusting for adiposity, insulin resistance, and inflammation, we found an independent association between the elevated PAI-1 levels and hepatic steatosis but we are not able to identify the causality. In addition, the sample was made up of overweight and obese Hispanic children, thereby potentially limiting the generalizability of our results to other ethnic groups.

In conclusion, our results show that hepatic steatosis in children is positively associated with plasma levels of PAI-1 independent of body weight, insulin resistance indices, and inflammatory markers. Our findings support further investigation of PAI-1 in NAFLD, particularly since it could serve as a therapeutic target benefiting both hepatic steatosis and the associated cardiovascular disease risk.

Acknowledgments

Support for these studies included grants from NIH K23 DK080953 (Vos), and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Foundation Nestle Young Investigator Award (Vos). Also supported by the National Center for Advancing Translational Sciences of the National Institutes of Health under Award Number UL1TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Financial Support: The study was funded, in part, from grants from the National Institutes of Health K23 DK080953, R01DK096157-01 (MBV), K24 DK096574 (TRZ), 1R01AA018869-01, 1U01AA021901-01 (CJM) and DoD W81XWH-11-1-0595 (CJM) and ACTSI grant UL1 TR000454. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

References


What is Known

- Nonalcoholic fatty liver disease is associated with increased risk of cardiovascular disease.
- Plasminogen activator inhibitor-1 (PAI-1) is an acute phase protein that is elevated in obesity and has been suggested to mediate the development of cardiovascular disease in NAFLD.
What is New

- PAI-1 is closely correlated with the quantity of hepatic steatosis in children independent of adiposity, insulin resistance indices, and inflammatory markers, supporting a possible role of PAI-1 in mediating NAFLD development and contributing to the increased cardiovascular risk as commonly seen in NAFLD.
Figure 1. Plasma concentration of PAI-1 significantly differed across the severity of hepatic steatosis

*p = 0.04 vs. normal hepatic fat group. ** p < 0.001 vs. normal hepatic fat group. # p = 0.002 vs. low hepatic fat group.
Table 1

Demographic and laboratory characteristics of the study population

<table>
<thead>
<tr>
<th>Parameters</th>
<th>NHF (N=12)</th>
<th>LHF (N=14)</th>
<th>HHF (N=13)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>14.6 (0.54)</td>
<td>13.9 (0.62)</td>
<td>13.7 (0.78)</td>
<td>0.621</td>
</tr>
<tr>
<td>Male (n, %)</td>
<td>5 (41.7)</td>
<td>2 (14.3)</td>
<td>9 (69.2)</td>
<td>0.015</td>
</tr>
<tr>
<td>BMI z-score</td>
<td>1.95 (0.08)</td>
<td>2.01 (0.08)</td>
<td>2.30 (0.12)</td>
<td>0.030</td>
</tr>
<tr>
<td>Visceral adiposity (cm²)</td>
<td>89.7 (11.4)</td>
<td>72.8 (7.08)</td>
<td>129 (13.8)</td>
<td>0.010</td>
</tr>
<tr>
<td>Hepatic steatosis (%)</td>
<td>3.96 (0.19)</td>
<td>7.26 (1.65)</td>
<td>15.9 (4.48)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>17.3 (2.15)</td>
<td>17.1 (1.05)</td>
<td>94.3 (36.2)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Glucose (mg/dl)</td>
<td>72.8 (7.31)</td>
<td>122 (14.4)</td>
<td>201 (32.7)</td>
<td>0.769</td>
</tr>
<tr>
<td>Insulin (mU/L) *</td>
<td>17.1 (2.15)</td>
<td>27.7 (22.1)</td>
<td>46.3 (12.9)</td>
<td>0.012</td>
</tr>
<tr>
<td>HOMA-IR *</td>
<td>3.92 (0.44)</td>
<td>6.89 (1.66)</td>
<td>11.3 (4.01)</td>
<td>0.028</td>
</tr>
<tr>
<td>Adipo-IR *</td>
<td>13.1 (1.60)</td>
<td>23.8 (5.99)</td>
<td>85.3 (46.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>Cholesterol (mg/dl)</td>
<td>157 (22.1)</td>
<td>161 (8.78)</td>
<td>176 (12.0)</td>
<td>0.354</td>
</tr>
<tr>
<td>TG (mg/dl)</td>
<td>72.8 (7.31)</td>
<td>122 (14.4)</td>
<td>201 (32.7)</td>
<td>0.001</td>
</tr>
<tr>
<td>LDL (mg/dl)</td>
<td>99.3 (8.28)</td>
<td>105 (6.56)</td>
<td>109 (9.69)</td>
<td>0.720</td>
</tr>
<tr>
<td>HDL (mg/dl)</td>
<td>46.9 (2.51)</td>
<td>42.9 (7.98)</td>
<td>44.1 (10.8)</td>
<td>0.542</td>
</tr>
<tr>
<td>FFA (mEq/L)</td>
<td>0.81 (0.08)</td>
<td>0.85 (0.07)</td>
<td>1.31 (0.80)</td>
<td>0.032</td>
</tr>
<tr>
<td>hs-CRP (mg/L)</td>
<td>3.46 (1.03)</td>
<td>3.12 (0.64)</td>
<td>6.52 (2.18)</td>
<td>0.315</td>
</tr>
<tr>
<td>TNF-α (pg/mL) *</td>
<td>4.54 (0.61)</td>
<td>4.92 (0.46)</td>
<td>6.34 (0.62)</td>
<td>0.081</td>
</tr>
</tbody>
</table>

Data are expressed as mean (SE). p-values were generated by ANOVA or Kruskal-Wallis tests (for variables not normally distributed). Significant p-values (p < 0.05) marked in bold.

*NHF, n=10; LHF, N=13; HHF, N=8;

*HHF, n=11.

Abbreviations: NHF, normal hepatic fat (<5%); LHF, low hepatic fat (5–10%); HHF, high hepatic fat (>10%); ALT, alanine aminotransferase; HOMA-IR, homeostatic model assessment for insulin resistance index; Adipo-IR, adipose insulin resistance index; TG, triglycerides; LDL, low-density lipoprotein; HDL, high-density lipoprotein; FFA, free fatty acids; hs-CRP, high sensitivity C-reactive protein; TNF-α, tumor necrosis factor-α.
Table 2
β coefficients for the association between plasma PAI-1 concentrations and hepatic steatosis.

<table>
<thead>
<tr>
<th>Linear regression covariates</th>
<th>β (SEE)</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Model 1: BMI z-score</td>
<td>0.614 (0.165)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Model 2: BMI z-score, visceral adiposity</td>
<td>0.686 (0.253)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Model 3: BMI z-score, visceral adiposity, insulin resistance indices</td>
<td>0.599 (0.279)</td>
<td>0.004</td>
</tr>
<tr>
<td>Model 4: BMI z-score, visceral adiposity, insulin resistance indices, ALT, TNF-α</td>
<td>0.575 (0.320)</td>
<td>0.013</td>
</tr>
<tr>
<td>Model 5: BMI z-score, visceral adiposity, insulin resistance indices, ALT, TNF-α, plasma TG</td>
<td>0.292 (0.334)</td>
<td>0.204</td>
</tr>
</tbody>
</table>

Insulin resistance indices include plasma insulin, HOMA-IR, and Adipo-IR index.